Can digital Cognitive Behavioral Therapy (CBTi) become the universal first-line treatment for insomnia?

__________ Pear Therapeutics’ digital insomnia therapeutic will put FDA’s PreCert framework through its paces (MobiHealthNews): “Prescription digital therapeutics company Pear Therapeutics announced late last week that it has filed an FDA marketing authorization for Somryst, its digital cognitive behavioral therapy for the treatment of adults with chronic insomnia and depression. While an approval from the agency would mark the third authorized prescription digital therapeutic for Pear — behind reSET for substance use disorder and reSET-O for opioid use disorder — the Somryst application is also the first product to CEO and President Dr. Corey McCann’s knowledge submitted through the FDA’s Precertification Program’s Working Model … if cleared, Somryst’s digital nature could address the scaling and dependency issues that current treatments for chronic insomnia and depression face, McCann said. “CBTi is currently mandated as first line treatment for insomnia, but it is very very difficult for patients to receive in the real world because clinicians just aren’t sufficiently trained nor are they [incentivized] to provide face-to-face therapy of this degree of rigor,” he said. “So you can think of this as fitting into a paradigm for treating chronic insomnia as a first line treatment, and I think this is in very nice contrast to pharmacotherapies for insomnia. Things like zolpidem and benzodiazepines, which are better used in a short-term context, also ...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Cognitive Neuroscience Health & Wellness Technology CBT CBTi chronic insomnia cognitive-behavioral-therapy depression digital cognitive behavioral therapy digital therapeutics FDA Pear Therapeutics pharmacotherapies Precertificat Source Type: blogs